As the new year begins, pharmaceutical and biotechnology companies are preparing for big changes. Healthcare reform, constrained capital markets, and a shifting regulatory environment all spell new challenges for the industry. We continue with the second part of our year-end conversation with G. Steven Burrill, CEO of Burrill & Company and the publisher of The Burrill Report, with a look ahead to 2010 and beyond, what companies are doing to adapt to the changing environment, and whether or not the worst is over.
No comments:
Post a Comment